FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: RVV

  • Home
  •  | 
  • Tag Archives: "RVV"

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis

TORONTO, June 27, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) ("Revive" or the "Company"), a company focused on the research, development and commercialization of novel cannabinoid-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the treatment of autoimmune hepatitis (“AIH”) to Revive.
Read more

WeedMD and Revive Therapeutics Sign Medical Cannabis R&D Supply and Collaboration Agreements

WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD”), a federally-licensed producer and distributor of medical cannabis, and Revive Therapeutics Ltd. (TSX-V:RVV) (OTCQB:RVVTF) (FSE:31R)(“Revive”), a company focused on the research, development and commercialization of novel cannabinoid-based therapies, are pleased to announce they have entered into medical cannabis research and development supply and collaboration agreements (the “Agreements”).
Read more